De Pascale Maria Rosaria, Lanza Michele, Sommese Linda, Napoli Claudio
U.O.C. Immunohematology, Transfusion Medicine and Transplant Immunology, Regional Reference Laboratory of Transplant Immunology, Azienda Ospedaliera Universitaria (AOU), Second University of Naples, 80100 Naples, Italy.
Multidisciplinary Department of Medical, Surgical and Dental Sciences, Second University of Naples, 80100 Naples, Italy.
J Ophthalmol. 2015;2015:396410. doi: 10.1155/2015/396410. Epub 2015 Oct 4.
Human serum contains a physiological plethora of bioactive elements naturally released by activated platelets which might have a significant effect on the regeneration of corneal layers by stimulating the cell growth. This mechanism supported the use of human serum eye drops in some ocular diseases associated with dystrophic changes and alterations of the tear film, such as persistent corneal epithelial defects and dry eye syndrome. We focused our effort on potential benefits and limitations of the use of human serum eye drops when conventional therapies failed. We reviewed the recent literature by reporting published studies from 2010 to 2014. Despite the limited evaluated study populations, most of the clinical studies have confirmed that serum eye drop therapy is effective in corneal healing by reducing ocular symptom, particularly during the short-term follow-up. In addition, three recent published studies have shown the efficacy of the serum eye drop therapy in comparison to traditional ones in intractable patients. Besides, reported ongoing clinical studies confirmed the open debate regarding the use of biologic tools for cornea regeneration. Results from these studies might open novel challenges and perspectives in the therapy of such refractory patients.
人血清中含有大量由活化血小板自然释放的生物活性元素,这些元素可能通过刺激细胞生长对角膜各层的再生产生显著影响。这一机制支持了在一些与营养不良性变化和泪膜改变相关的眼部疾病中使用人血清滴眼液,如持续性角膜上皮缺损和干眼综合征。当传统疗法无效时,我们重点关注了使用人血清滴眼液的潜在益处和局限性。我们通过报告2010年至2014年发表的研究对近期文献进行了综述。尽管评估的研究人群有限,但大多数临床研究已证实,血清滴眼液疗法在角膜愈合方面是有效的,可减轻眼部症状,尤其是在短期随访期间。此外,最近发表的三项研究表明,在难治性患者中,血清滴眼液疗法比传统疗法更有效。此外,报告中的正在进行的临床研究证实了关于使用生物工具进行角膜再生的公开辩论。这些研究结果可能为这类难治性患者的治疗带来新的挑战和前景。